A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection
详细信息 查看全文
- 作者：Alberto Monroy-García (1) (3) (6)
Miguel A Gómez-Lim (2)
Benny Weiss-Steider (3) (6)
Paz-de Georgina la Rosa (2)
Jorge Hernández-Montes (3) (6)
Karyna Pérez-Salda?a (1)
Yessica S Tapia-Guerrero (3) (6)
Mariel E Toledo-Guzmán (3) (6)
Edelmiro Santiago-Osorio (4)
Héctor I Sanchez-Pe?a (5)
de Lourdes María Mora-García (3) (6) - 刊名：Virology Journal
- 出版年：2011
- 出版时间：December 2011
- 年：2011
- 卷：8
- 期：1
- 全文大小：335KB
- 参考文献：1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. / J Clin Pathol 2002, 55:244-65.
2. Evans MF, Adamson CS, Schned LM, St John TL, Leiman G, Ashikaga T, Cooper K: HPV is detectable in virtually all abnormal cervical cytology samples after reinvestigation of HPV negatives with multiple alternative PCR tests. / Diagn Mol Pathol 2010, 19:144-50. CrossRef
3. Doorbar J: Molecular biology of human papillomavirus infection and cervical cancer. / Clinical Science 2006, 110:525-41. CrossRef
4. Moody CA, Laimins LA: Human papillomavirus oncoproteins: pathways to transformation. / Nat Rev Cancer 2010, 10:550-60. CrossRef
5. Zhou J, Sun XY, Stenzel DJ, Frazer IH: Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. / Virology 1991, 185:251-57. CrossRef
6. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. / Proc Natl Acad Sci USA 1992, 89:12180-2184. CrossRef
7. Hagensee ME, Yaegashi N, Galloway DA: Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. / J Virol 1993, 67:315-22.
8. Rose RC, Bonnez W, Reichman RC, Garcea RL: Expression of human papillomavirus type 11 L1 protein in insect cells in vivo and in vitro assembly of viruslike particles. / J Virol 1993, 67:1936-944.
9. Biemelt S, Sonnewald U, Galmbacher P, Willmitzer L, Muller M: Production of human papillomavirus type 16 virus-like particles in transgenic plants. / J Virol 2003, 77:9211-212. CrossRef
10. Ochi H, Kondo K, Matsumoto K, Oki A, Yasugi T, Furuta R, Hirai Y, Yoshikawa H, Kanda T: Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia. / Clin Vaccine Immunol 2008, 15:1536-540. CrossRef
11. Wideroff L, Schiffman M, Haderer P, Armstrong A, Greer CE, Manos MM, Burk RD, Scott DR, Sherman ME, Schiller JT, Hoover RN, Tarone RE, Kirnbauer R: Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions. / J Infect Dis 1999, 180:1424-428. CrossRef
12. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA: Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. / J Infect Dis 2000, 181:1911-919. CrossRef
13. Sasagawa T, Inoue M, Lehtinen M, Zhang W, Gschmeissner SE, Hajibagheri MA, Finch J, Crawford L: Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions. / Clin Diagn Lab Immunol 1996, 3:403-10.
14. Heim K, Widschwendter A, Pirschner G, Wieland U, Awerkiew S, Christensen ND, Bergant A, Marth C, H?pfl R: Antibodies to human papillomavirus 16 L1 virus-like particles as an independent prognostic marker in cervical cancer. / Am J Obstet Gynecol 2002, 186:705-11. CrossRef
15. Viscidi RP, Kotloff KL, Clayman B, Russ K, Shapiro S, Shah KV: Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. / Clin Diagn Lab Immunol 1997, 4:122-26.
16. Sasagawa T, Yamazaki H, Dong YZ, Satake S, Tateno M, Inoue M: Immunoglobulin- A and -G responses against virus-like particles (VLP) of human papillomavirus type in women with cervical cancer and cervical intra-epithelial lesions. / Int J Cancer 1998, 75:529-35. CrossRef
17. Lehtinen M, Dillner J, Knekt P, Luostarinen T, Aromaa A, Kirnbauer R, Koskela P, Paavonen J, Peto R, Schiller JT, Hakama M: Serologically diagnosed infection with human papillomavirustype 16 and risk for subsequent development of cervical carcinoma: nested case-control study. / BMJ 1996, 312:537-39.
18. Lehtinen M, Pawlita M, Zumbach K, Lie K, Hakama M, Jellum E, Koskela P, Luostarinen T, Paavonen J, Pukkala E, Sigstad E, Thoresen S, Dillner J: Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. / Am J Obstet Gynecol 2003, 188:49-5. CrossRef
19. Park JS, Park DC, Kim CJ, Ahn HK, Um SJ, Park SN, Kim SJ, Namkoong SE: HPV-16-related proteins as the serologic markers in cervical neoplasia. / Gynecol Oncol 1998, 69:47-5. CrossRef
20. Viscidi RP, Sun Y, Tsuzaki B, Bosch FX, Munoz N, Shah KV: Serologic response in human papillomavirus-associated invasive cervical cancer. / Int J Cancer 1993, 55:780-84. CrossRef
21. Paz de la Rosa G, Monroy-García A, Mora-García ML, Reynaga Pe?a CG, Hernández-Montes J, Benny Weiss-Steider B, Gómez Lim MA: An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice. / Virol J 2009, 6:2. CrossRef
22. Rocha-Zavaleta L, Ambrosio JP, Mora-Garcia ML, Cruz-Talonia F, Hernandez-Montes J, Weiss-Steider B, Ortiz-Navarrete V, Monroy-Garcia A: Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low- risk HPV-associated low-grade squamous intraepithelial lesions. / J Gen Virol 2004, 85:2643-650. CrossRef
23. Palmroth J, Namujju P, Simen-Kapeu A, Kataja V, Surcel HM, Tuppurainen M, Yliskoski M, Syrj?nen K, Lehtinen M: Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes. / Scand J Infect Dis 2010, 42:379-84. CrossRef
24. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J, Kiviat N, Galloway DA: The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. / J Infect Dis 1996, 174:927-36. CrossRef
25. Nakagawa M, Viscidi R, Deshmukh I, Costa MD, Palefsky JM, Farhat S, Moscicki AB: Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women. / Clin Diagn Lab Immunol 2002, 9:877-82.
26. Roden RB, Hubbert NL, Kirnbauer R, Breitburd F, Lowy DR, Schiller J: Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. / J Virol 1995, 69:5147-151.
27. Bian T, Wang Y, Lu Z, Ye Z, Zhao L, re J, Zhang H, Ruan L, Tian H: Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice. / Mol Cancer Ther 2008, 7:1329-335. CrossRef
28. Müller M, Viscidi RP, Sun Y, Guerrero E, Hill PM, Shah F, Bosch FX, Mu?oz N, Gissmann L, Shah KV: Antibodies to HPV-16 E6 and E7 proteins as markers for HPV- 16 associated invasive cervical cancer. / Virology 1992, 187:508-14. CrossRef
29. Rosales R, López-Contreras M, Cortes RR: Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA. / J Med Virol 2001, 65:736-4. CrossRef
30. Vernon SD, Unger ER, Miller DL, Lee DR, Reeves WC: Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival From cervical cancer. / In J Cancer 1997, 74:50-6.
31. Papenfuss M, Schneider A, Nour M, Hatch K: Risk factors for high-risk type human papillomavirus infection among Mexican-American women. / Cancer Epidemiol Biomarkers Prev 1999, 8:615-20.
32. Smith EM, Johnson SR, Jiang D, Zaleski S, Lynch CF, Brundage S, Anderson RD, Turek LP: The association between pregnancy and human papilloma virus prevalence. / Cancer Detect Prev 1991, 15:397-02.
33. Meschede W, Zumbach K, Braspenning J, Scheffner M, Benitez-Bribiesca L, Luande J, Gissmann L, Pawlita M: Antibodies against early proteins of human papillomavirus as diagnostic markers for invasive cervical cancer. / J Clin Microbiol 1998, 36:475-80.
34. Di Bonito P, Grasso F, Mochi S, Accardi L, Donà MG, Branca M, Costa S, Mariani L, Agarossi A, Ciotti M, Syrj?nen K, Giorgi C: Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins. / Infect Agent Cancer 2006, 1:6. CrossRef
35. Jochmus-Kudielka I, Schneider A, Braun R, Kimmig R, Koldovsky U, Schneweis KE, Seedorf K, Gissmann L: Antibodies against the human papillomavirus type 16 early proteins in human sera: Correlation of anti-E7 reactivity with cervical cancer. / J Natl Cancer Inst 1989, 81:1698-704. CrossRef
36. Bleul C, Müller M, Frank R, Gausepohol U, Koldovsky U, Mgaya HN, Luande J, Pawlita M, Meulen JT, Viscidi R, Gissmann L: Human papillomavirus type 18 E6 and E7 antibodies in human sera: Increased anti-E7 prevalence in cervical cancer patients. / J Clin Microbiol 1991, 29:1579-588.
37. Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM, Gallee MP, Hart AA, Müller M, Trimbos JB, Helmerhorst TJ: Prognostic significance of serum antibodies to human papillomavirus-16 E4 and E7 peptides in cervical cancer. / Cancer 1994, 74:2307-313. CrossRef
38. Malik ZA, Hailpern SM, Burk RD: Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. / Viral Immunol 2009, 22:445-49. CrossRef
39. Richardt RM: Natural history of cervical intraepithelial neoplasia. / Clin Obstet Gynecol 1968, 10:748-84.
40. Kaye JN, Cason J, Pakarian FB, Jewers RJ, Kell B, Bible J, Raju KS, Best JM: Viral load as a determinant for transmission of human papillomavirus type 16 from mother to child. / J Med Virol 1994, 44:415-21. CrossRef
41. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM: Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. / Cancer Cells 1989, 7:209-14.
42. Karlsen F, Kalantari M, Jenkins A, Pettersen E, Kristensen G, Holm R, Johansson B, Hagmar B: Use of multiple PCR primer sets for optimal detection of Human papillomavirus. / J Clin Microbiol 1996, 34:2095-100.
43. Saiki RA, Bugawan TL, Horn GT, Mullis KB, Erlich HA: Analysis of enzymatically amplified b-globin and HLA DQ alpha DNA with allele specific oligonucleotide probes. / Nature 1986, 324:163-66. CrossRef
44. Monroy-García A, Hernández-Montes J, Mora-García ML: Identification of epitopes from L1, E6, and E7 proteins of the HPV-16 and 18 types and its implication for diagnosis and treatment of cervical carcinoma. In / Advances in Cancer Research at UNAM (Universidad Nacional Autónoma de México) Edited by: Jaime Mas Oliva. 2007, 1-2. / Manual Moderno, UNAM, ISBN 970-2-283-;
45. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ: Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA- A*0201-binding peptides. / J Immunol 1995, 154:5934-943.
46. Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, He W, Romney SL, Johnson A, Angeletti R, Abadi M: Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. / Cancer Epidemiol Biomarkers Prev 2002, 11:483-88.
47. Khammanivong V, Liu XS, Liu WJ, Rodda SJ, Leggatt GR, Tndle RW, Frazer IH, Fernando GJ: Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16. / Immunol Cell Biol 2003, 81:1-. CrossRef
48. Monroy-García A, Ortíz-Navarrete VF, Mora-García ML, Flores-Borja F, Diaz-Qui?onez A, Isibasi-Araujo A, Trejo-Becerril C, Chacón-Salinas R, Hernández-Montes J, Granados-Arreola J, de Leo C, Weiss-Steider B: Identification of peptides presented by HLA class I molecules on cervical cancer cells with HPV-18 infection. / Immunol Lett 1999, 67:167-77. CrossRef - 作者单位：Alberto Monroy-García (1) (3) (6)
Miguel A Gómez-Lim (2)
Benny Weiss-Steider (3) (6)
Paz-de Georgina la Rosa (2)
Jorge Hernández-Montes (3) (6)
Karyna Pérez-Salda?a (1)
Yessica S Tapia-Guerrero (3) (6)
Mariel E Toledo-Guzmán (3) (6)
Edelmiro Santiago-Osorio (4)
Héctor I Sanchez-Pe?a (5)
de Lourdes María Mora-García (3) (6)
1. Unidad de Investigación Médica en Enfermedades Oncológicas., IMSS, CMN SXXI, Guanajuato, México
3. Laboratorio de Inmunobiología, Unidad de Investigación en Diferenciación Celular y Cáncer., UNAM, FES-Zaragoza, México
6. Laboratorio 3, PB, UMIEZ. Campus II. Facultad de Estudios Superiores Zaragoza, UNAM, Batalla 5 de mayo s/n, Col. E. Oriente, Esquina Fuerte Loreto, Iztapalapa, CP 09230, México, DF., México
2. Centro de Investigación y de Estudios Avanzados (CINVESTAV), Unidad Irapuato, Guanajuato, México
4. Laboratorio de Hematopoyesis, Unidad de Investigación en Diferenciación Celular y Cáncer, UNAM, FES-Zaragoza, México
5. Departamento de Ginecología, IMSS, H.G.Z No. 2-A, Troncoso, Mexico - ISSN：1743-422X
文摘
Background The presence of IgG antibodies to HPV-16 L1-virus like particles (VLPs) in serum has been reported as a result of persistent exposure to the virus and as a marker of disease progression. However, detection of VLP-specific antibodies in sera does not always indicate a malignant lesion as positive results may also be due to a nonmalignant viral infection. Furthermore, malignant lesions are associated with an increased antibody titer for E6 and E7 proteins. The aim of this study was to develop an ELISA using a novel chimeric virus-like particle (cVLP) encoding an L1 protein fused with a string of HPV-16 E6 and E7 seroreactive epitopes to its C-terminus to be used for detection of HPV-16 specific antibodies in patients with cervical intraepithelial lesion grade 1 (CIN 1). Results The sera of 30 patients with CIN 1 who also tested positive for HPV-16 DNA and of 30 age-matched normal donors negative for HPV infection were tested for the presence of IgG antibodies specific for either VLP-L1 (HPV-16 L1), gVLP (derived from Gardasil), or cVLP by ELISA. The cVLP-reactive sera yielded two distinct groups of results: (H) reactivity levels that presented very strong cVLP-specific titers, and (L) reactivity levels with significantly lower titers similar to those obtained with VLP-L1 and gVLP antigens. Additionally, the sera that presented the higher cVLP titers closely matched those that had significantly stronger reactivity to E6 and E7 epitopes. Interestingly, the samples with the highest titers corresponded to patients with the higher numbers of sexual partners and pregnancies. On the other hand only 4 out of the 12 sera that harbored antibodies with VLP neutralizing ability corresponded to the group with high cVLP antibody titers. Conclusion We report for the first time that chimeric particles containing HPV-16 L1 protein fused with E6 and E7 seroreactive epitopes enable much better detection of IgG antibodies in the sera of CIN 1 patients positive for HPV-16 infection than those obtained with VLPs containing only the HPV-16 L1 protein. We also found that the sera with higher cVLP antibody titers corresponded to patients with more sexual partners and pregnancies, and not always with to those with a high neutralizing activity. This novel assay could help in the development of a tool to evaluate cervical cancer risk.